This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Tarsus Pharmaceuticals’s 8K filing here.
About Tarsus Pharmaceuticals
Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.
Featured Articles
- Five stocks we like better than Tarsus Pharmaceuticals
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- 4 Social Media Stocks Set to Gain as TikTok Ban Looms
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- How Do Stock Buybacks Affect Shareholders?
- 3 Grocery Stocks That Are Proving They Are Still Essential
- JPMorgan Chase & Co. Stock Can Hit $300 This Year
